We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood-Based Diagnostic Test Detects Parkinson’s before Nervous System Damage Worsens

By LabMedica International staff writers
Posted on 01 Sep 2023
Print article
Image: The new blood test detects a key indicator of Parkinson’s disease (Photo courtesy of Freepik)
Image: The new blood test detects a key indicator of Parkinson’s disease (Photo courtesy of Freepik)

Parkinson’s disease affects around 10 million individuals across the globe, ranking as the second-most prevalent neurodegenerative disorder following Alzheimer’s. At present, diagnosis of Parkinson’s disease is dependent primarily on clinical symptoms, which often occur after significant neurological harm has already been done. In a major advancement, researchers have now developed a blood test with the capability to identify Parkinson’s disease, potentially enabling early diagnosis before the damage to the nervous system worsens.

To create their diagnostic tool, researchers led by a team of neuroscientists at Duke Health (Durham, NC, USA) focused on DNA damage in mitochondria. Mitochondria are like cell powerhouses, converting raw energy into the fuel that cells use. They have their own DNA, which can get damaged separately from the nuclear DNA that carries most of an organism's genetic information. Earlier research has linked mitochondrial DNA damage with a higher risk of Parkinson's disease. The Duke team used polymerase chain reaction (PCR) technology to develop a test that successfully measured higher levels of mitochondrial DNA damage in blood cells from people with Parkinson's disease compared to those without the condition.

The new test also found high levels of damaged DNA in the blood samples of people who have the LRRK2 genetic mutation, which has been linked to a higher risk of the disease. The test was able to identify Parkinson's patients with or without LRRK2 mutations. In further experiments on cells from Parkinson's patients, the PCR-based test showed that it could detect lower mitochondrial DNA damage in cells treated with a LRRK2 inhibitor compared to cells from patients who didn't receive the inhibitor. This suggests the test could help identify Parkinson's patients who might benefit from LRRK2 kinase inhibitor treatments, even if they don't have the LRRK2 mutation. The researchers now plan to test the assay on samples from people in the earliest stages of the disease before symptoms appear.

“A simple blood test would allow us to diagnose the disease earlier and start therapies sooner,” said senior author Laurie Sanders, Ph.D., an associate professor at the Duke School of Medicine. “Additionally, a clear-cut diagnosis would accurately identify patients who could participate in drug studies, leading to the development of better treatments and potentially even cures.”

Related Links:
Duke Health 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
New
PAPP-A Test
PAPP-A Mass Units AccuBind ELISA
New
Male Fertility Rapid Test
SP-10

Print article

Channels

Immunology

view channel
Image: Example image of the high-throughput microscopy method used in the study, showing immune cells stained with different fluorescence markers (Photo courtesy of Felix Kartnig/CeMM, MedUni Vienna)

Cutting-Edge Microscopy Technology Enables Tailored Rheumatology Therapies

Rheumatoid arthritis is the most common inflammatory joint disorder, with women three times as likely to suffer from the condition as men. Treatment advances made over the past decades have led to the... Read more

Microbiology

view channel
Image: RNA sequencing directly from whole blood aims to expand access to LRTI testing (Photo courtesy of CARB-X)

Novel Test to Diagnose Bacterial Pneumonia Directly from Whole Blood

Pneumonia and lower-respiratory-tract infections (LRTIs) are among the top causes of illness and death globally, particularly in vulnerable populations such as the elderly, young children, and immunocompromised... Read more

Pathology

view channel
Image: The new method uses DNA sequencing to measure metabolites (Photo courtesy of 123RF)

New Metabolite Detection Method Using DNA Sequencing Could Transform Diagnostics

Metabolites play a vital role as biomarkers that provide insights into our health, and when their levels go awry, it can lead to diseases such as diabetes and phenylketonuria. Quantifying metabolites remains... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.